BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

Company focus

• Clinical-stage biotechnology company developing cancer immunotherapies.
• Lead program: Bria-IMT™, a whole-cell immunotherapy for metastatic breast cancer (MBC) engineered to secrete GM-CSF and activate dendritic and T cells. Bria-IMT™ is being developed in combination with the PD-1 inhibitor retifanlimab in a pivotal Phase 3 trial (Bria-ABC, NCT06072612) and has FDA Fast Track designation.
• Additional platforms and programs:
  • Bria-OTS™: Personalized off-the-shelf immunotherapy using a panel of engineered cell lines to match HLA types; Phase 1/2a dose-escalation study ongoing (NCT06471673).
  • Bria-OTS+™: Enhanced off-the-shelf platforms with program-specific candidates (Bria-BRES+ for breast, Bria-PROS+ for prostate, Bria-LUNG+ for lung, Bria-MEL+ for melanoma, Bria-OVA+ for ovarian cancer) at various development stages.
  • BriaPro+ assets: sCD80-related therapies (sCD80 program transferred in 2026).
  • Additional preclinical and early-stage programs include Bria-BRES+™ and Bria-PROS+™; Bria-OVA+ and Bria-MEL+ milestones were reported in 2025–2026 updates.

Clinical and regulatory status

• Bria-IMT™ + retifanlimab is in a pivotal Phase 3 trial for advanced MBC; the primary endpoint is overall survival. The DSMB provided seven consecutive safety recommendations as of September 14, 2026.
• Phase 1/2 development of Bria-IMT™ in combination with immune checkpoint inhibitors completed; Phase 2 data reported in 2025–2026 showed overall survival and progression-free indicators in subgroups.
• Bria-OTS™ Phase 1/2 study is ongoing; an early single-agent administration produced complete resolution of a lung metastasis in one treated patient to date. Dose-escalation and combination cohorts are in progress.
• INDs for Bria-BRES+™ (breast) and Bria-PROS+™ (prostate) were cleared in 2026; Bria-PROS+ IND clearance and planned Phase 1/2a programs were announced.
• Bria-OVA+ and Bria-MEL+ remain in development with preclinical work presented at SITC/AACR in 2025–2026.
• Manufacturing and supply: Bria-IMT™ is produced under cGMP by FUJIFILM Diosynth Biotechnologies and UC Davis. In July 2026, arrangements expanded to FUJIFILM Biotechnologies California for Phase 3 supply.

Intellectual property

• Core Bria-IMT™ patent family covers SV-BR cells, compositions, and methods, with U.S. patents dating back to 2010 and related extensions.
• PCT national phase patents have been filed for Bria-OTS™ and related dendritic cell/immunotherapy technologies.
• sCD80 (soluble CD80) assets licensed from UMBC were transferred to BriaPro in 2026; multiple related patents exist, including U.S. and international filings.

Subsidiaries and corporate structure

• BriaPro Therapeutics Corp. holds the UMBC sCD80 assets and related programs. BriaPro became a two-thirds owned subsidiary following a spin-out arrangement, with asset transfers occurring between 2023 and 2026.
• By March 31, 2026, BriaPro acquired BriaCell’s exclusive license to develop and commercialize sCD80. BriaCell retained approximately a 78% stake in BriaPro after the transaction.

Market context

• Breast cancer incidence in the U.S. for 2026 is projected at roughly 324,580 new cases (about 322k women, 2,670 men), with ongoing unmet needs in metastatic disease.
• The global cancer drug market is expected to approach $467 billion by 2030 (as cited in company materials).
• BriaCell targets heavily pre-treated MBC populations, including HR+/HER2− and TNBC subtypes, and is pursuing biomarker-driven strategies to identify likely responders.

Financials and financing

• Net losses:
  • 2026: $34,904,262
  • 2025: $26,311,867
• Accumulated deficit: $146,659,826 as of July 31, 2026 (vs. $111,755,564 as of July 31, 2025).
• FY2026 gross proceeds raised: approximately $34.7 million.
  • January 2026 offering: $30.0 million gross via 5,366,726 units (common shares or pre-funded warrants) plus warrants; placement agent warrants issued.
  • June 2026 offering: approximately $4.7 million gross via a public offering of common shares; placement agent warrants issued.
• The company discloses material doubt about its ability to continue as a going concern and states that additional equity or debt financing will be required to fund anticipated operations.

Employees and facilities

• Employees: 31 full-time employees as of the filing date; an average of 26 employees for the fiscal year ended July 31, 2026; four executive officers.
• Locations: Corporate and R&D offices in West Vancouver, BC, Canada, and Philadelphia, PA, USA. The company relies on third-party manufacturing and contract research/manufacturing partners and does not own real property.
• Key manufacturing relationships include UC Davis and FUJIFILM Diosynth, with Phase 3 supply expanded to FUJIFILM Biotechnologies California in June 2026.

Regulatory and compliance posture

• BriaCell operates under regulatory oversight from the FDA, Health Canada, and other foreign authorities. The company has pursued regulatory pathways including Fast Track and priority review and may seek Breakthrough Therapy designation if supported by clinical data. Phase 3 results could support a BLA submission if predefined efficacy thresholds are met.
• The company relies on third-party CROs, CMOs, and collaborators for clinical development, manufacturing, and regulatory submissions.
• Privacy and compliance considerations include HIPAA/HITECH and international data privacy requirements, with potential penalties for non-compliance.

Summary takeaway

BriaCell is a clinical-stage immunotherapy company focused on Bria-IMT™ for metastatic breast cancer and a broader Bria-OTS+ platform for personalized, off-the-shelf therapies. The company maintains a small internal team, outsources manufacturing and trials, and advanced a Phase 3 program for Bria-IMT™ in combination with a PD-1 inhibitor. BriaCell reported material net losses and an accumulated deficit, raised approximately $34.7 million in fiscal 2026, and continues to pursue regulatory and development milestones across Bria-IMT™, Bria-OTS+, and BriaPro sCD80 assets.